MiNK Therapeutics increased investment in its iNKT platform led to a higher net loss in Q3 2025. The company highlighted durable responses from its lead therapy agenT-797 and secured non-dilutive funding for a new GvHD trial, while extending its cash runway through 2026.
Reported net loss of $2.9 million for Q3 2025, compared to $1.8 million in Q3 2024
Cash and cash equivalents stood at $14.3 million as of September 30, 2025
Received NIH and philanthropic funding to support a new GvHD trial with agenT-797
Extended cash runway through 2026 following an additional $1.2 million raised post-quarter
MiNK Therapeutics anticipates initiating multiple studies in 2026, with early clinical readouts expected from its pulmonary and oncology programs, supported by strategic partnerships and grant funding.
Analyze how earnings announcements historically affect stock price performance